Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Intel (INTC.O) to acquire quantum startup Classiq for about $2.3 billion.
2026-10-27
Intel (INTC.O) to acquire quantum startup Classiq for about $2.3 billion.
Back
Other News
2026-10-27
According to Bagheri, deputy secretary of Iran's Supreme National Security Council, it was the Pakistani Army Chief of Staff who proposed the "Israel-Shah-Turkish-Pakistan" four-party talks.
According to Bagheri, deputy secretary of Iran's Supreme National Security Council, it was the Pakistani Army Chief of Staff who proposed the "Israel-Shah-Turkish-Pakistan" four-party talks.
2026-10-27
Changchun High & New Technology Industry (Group) Co., Ltd’s unit Changchun Jinsai Pharmaceutical Co., Ltd received a Drug Clinical Trial Approval Notice from the National Medical Products Administration approving a domestically manufactured drug‑regi
Changchun High & New Technology Industry (Group) Co., Ltd’s unit Changchun Jinsai Pharmaceutical Co., Ltd received a Drug Clinical Trial Approval Notice from the National Medical Products Administration approving a domestically manufactured drug‑registration clinical trial application for injectable GenSci136. GenSci136 is Jinsai’s self‑developed BAFF/APRIL dual‑target antagonist, classified in China as a Class 1 therapeutic biological product and intended for treatment of Sjögren’s syndrome.
Chat with us
, powered by
LiveChat